Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 4Thoracic 2Gynecologic 2Gastrointestinal 2Tumor-Agnostic 1Other solid neoplasm 1Head & Neck 1

Conditions

Triple Negative Breast Neoplasms 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 263Radiotherapy 166Cetuximab 159Docetaxel 105Fluorouracil 104pembrolizumab 94Radiotherapy, Intensity-Modulated 83Carboplatin 80Paclitaxel 73Nivolumab 59Erlotinib Hydrochloride 35Surveys and Questionnaires 32Gemcitabine 32durvalumab 30Radiation 29Drug Therapy 25Immunohistochemistry 21Gefitinib 21Capecitabine 21tremelimumab 18Bevacizumab 18Surgical Procedures, Operative 17Sorafenib 17Magnetic Resonance Spectroscopy 17Ipilimumab 17Pemetrexed 16lenvatinib 15atezolizumab 15Radiosurgery 15Gene Expression Profiling 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × seribantumab × Head & Neck × Clear all
NCT01451632 2016-09-08

A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers

Merrimack Pharmaceuticals

Phase 1 Completed
48 enrolled 14 charts
BreastGastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡